BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Liang B, Hu X, Ding Y, Liu M. Tumor-derived exosomes in the PD-1/PD-L1 axis: Significant regulators as well as promising clinical targets. J Cell Physiol 2021;236:4138-51. [PMID: 33275291 DOI: 10.1002/jcp.30197] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Liu J, Chen Z, Li Y, Zhao W, Wu J, Zhang Z. PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy. Front Pharmacol 2021;12:731798. [PMID: 34539412 DOI: 10.3389/fphar.2021.731798] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Whiteside TL, Diergaarde B, Hong CS. Tumor-Derived Exosomes (TEX) and Their Role in Immuno-Oncology. Int J Mol Sci 2021;22:6234. [PMID: 34207762 DOI: 10.3390/ijms22126234] [Reference Citation Analysis]
3 Cheng Y, Shi D, Xu Z, Gao Z, Si Z, Zhao Y, Ye R, Fu Z, Fu W, Yang T, Xiu Y, Lin Q, Cheng D. 124I-Labeled Monoclonal Antibody and Fragment for the Noninvasive Evaluation of Tumor PD-L1 Expression In Vivo. Mol Pharm 2022. [PMID: 35244407 DOI: 10.1021/acs.molpharmaceut.2c00084] [Reference Citation Analysis]
4 Rasihashemi SZ, Rezazadeh Gavgani E, Majidazar R, Seraji P, Oladghaffari M, Kazemi T, Lotfinejad P. Tumor-derived exosomal PD-L1 in progression of cancer and immunotherapy. J Cell Physiol 2021. [PMID: 34825383 DOI: 10.1002/jcp.30645] [Reference Citation Analysis]
5 Xue D, Han J, Liu Y, Tuo H, Peng Y. Current perspectives on exosomes in the diagnosis and treatment of hepatocellular carcinoma (review). Cancer Biol Ther 2021;22:279-90. [PMID: 33847207 DOI: 10.1080/15384047.2021.1898728] [Reference Citation Analysis]
6 Bailly C, Thuru X, Quesnel B. Soluble Programmed Death Ligand-1 (sPD-L1): A Pool of Circulating Proteins Implicated in Health and Diseases. Cancers (Basel) 2021;13:3034. [PMID: 34204509 DOI: 10.3390/cancers13123034] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Huang X, Chen L, Li Z, Zheng B, Liu N, Fang Q, Jiang J, Rao T, Ouyang D. The efficacy and toxicity of antineoplastic antimetabolites: Role of gut microbiota. Toxicology 2021;460:152858. [PMID: 34273448 DOI: 10.1016/j.tox.2021.152858] [Reference Citation Analysis]
8 Zouein J, Kesrouani C, Kourie HR. PD-L1 expression as a predictive biomarker for immune checkpoint inhibitors: between a dream and a nightmare. Immunotherapy 2021;13:1053-65. [PMID: 34190579 DOI: 10.2217/imt-2020-0336] [Reference Citation Analysis]
9 Chan MH, Chang ZX, Huang CF, Lee LJ, Liu RS, Hsiao M. Integrated therapy platform of exosomal system: hybrid inorganic/organic nanoparticles with exosomes for cancer treatment. Nanoscale Horiz 2022. [PMID: 35043812 DOI: 10.1039/d1nh00637a] [Reference Citation Analysis]
10 Wu Q, Chen Y, Li Q, Chen J, Mo J, Jin M, Yang Q, Rizzello L, Tian X, Luo L. Time Rules the Efficacy of Immune Checkpoint Inhibitors in Photodynamic Therapy. Adv Sci (Weinh) 2022;:e2200999. [PMID: 35470595 DOI: 10.1002/advs.202200999] [Reference Citation Analysis]